Comprehensive Blood Cancer NGS Assays

Next-gen mutation detection for myeloid and lymphoid malignancies

Comprehensive mutational profiling in blood cancers is increasingly important, yet there are challenges with existing NGS-based approaches. Complex mutation types like gene fusions and FLT3-ITDs are difficult for standard chemistries and bioinformatic approaches. Critical genomic regions like CEBPA are notoriously difficult to detect variants with confidence. Archer's proprietary AMP™ chemistry and purpose-built bioinformatic suite — Archer Analysis — address these critical concerns.

From easy-to-use lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, indels, CNVs and RNA abundance. Post-sequencing, Archer Analysis incorporates state-of-the-art error correction and noise characterization for confident mutation detection and reporting from a simple user interface.


Hover over individual panels for a quick preview or click for even more information

RNA input


DNA input


Small

Medium

Large

Need to modify a panel?

AMP chemistry is flexible and gene-level probe sets are modular. This means that any of our 94 wet lab-validated designs can be added to any preconfigured panel to build assays that fit your research goals. Archer Assay Designer gives you the power to easily determine assay content and keep current with the latest research.


Capabilities


Gene fusion detection

Best-in-class detection of known and novel gene fusions with integrated Quiver™ fusion database


Splicing

Precise breakpoint identification of splicing events like MLL, PTD and IKZF1


SNV

Confidently detect SNVs with powerful sequencing noise characterization and molecular barcodes, even in tough regions like CEBPα


Expression profiling

Differentiate lymphoma subtypes with molecular barcode-enabled single-gene expression level in critical genes like PDL1 and multi-gene expression signatures


Complex mutation detection

AMP technology and purpose-built analysis enable robust detection of complex mutations like the large CALR deletion and the widely variable and important FLT3-ITDs


CNV

Unique molecule counting enables sensitive CNV detection at single-gene level or chromosomal arm deletion/gain inference


Gene fusion frustration? Fusions are challenging!


MLL/KMT2A and fusion partners. 85 recurrent translocations with 66 partner genes.

Gene fusions are frequently observed in hematologic malignancies. For example, 302 fusions have been identified in AML and 237 fusions have been identified in ALL, and in both cases over 50 of these fusions are recurrent (F. Mertens et al, 2015). Furthermore, some genes are highly promiscuous, forming fusions with multiple different gene partners. An example of this is shown adjacently, where greater than 66 fusion partners have been discovered for MLL (or KMT2A), a frequently rearranged gene in AML. While break-apart FISH (below) can detect both known and novel fusions, it lacks the scalability to detect multiple fusions in a single sample. NGS-based methods enable highly multiplexed interrogation of gene fusions, however opposing-primer based techniques (bottom right) that are used to enrich for target regions of interest require prior knowledge of both fusion partners, thus limiting their ability to detect novel fusions. As new fusions are continually discovered, designing new primers to detect each new fusion partner is impractical.

Breakapart FISH probe

Ambiguous fluorescence in-situ hybridization (FISH) assay results for an MLL fusion.

Opposing primers don't find novel fusions

Traditional opposing primer-based PCR misses novel KMT2A fusions for PCR/qPCR/RT-PCR assays



FLT3-ITDs are accurately detected


FLT3-ITD shown in Archer Analysis

Open-ended amplification with defined read structure allows for de novo assembly and robust ITD detection of all sizes and integration sites.

Internal tandem duplications (ITDs) in FLT3 are common oncogenic drivers in AML which often coexist with other types of driver mutations. Although NGS simultaneously detects multiple mutation types in a single sample, ITDs pose unique challenges to NGS methods, in part because of their highly variable nature and the difficulties of mapping repeated sequences to a wild-type reference. AMP technology permits complete, bidirectional coverage of ITD-containing regions, and the Archer Analysis pipeline enables de novo assembly of sequencing reads to generate a consensus sequence. As shown in the figure above, AMP-based NGS in combination with Archer Analysis enabled FLT3-ITD detection from blood samples in concordance with capillary gel electrophoresis (CGE), the current gold standard method for ITD detection.

Watch the video: FLT3-ITD Detection With Archer Blood Cancer Assays

The molecular landscape of leukemia and lymphoma has expanded exponentially in the last two decades, and the complexity and scope of biomarkers makes molecular analysis difficult for any single approach. Archer Blood Cancer assays are powered by AMP target enrichment chemistry to detect multiple mutation types and gene expression profiling in a single sample.

 



Molecular barcodes can reveal relative expression levels of select genes


Molecular barcodes ligated to RNA fragments prior to amplification enable determination of relative abundance of unique RNA fragments. This information can be used to assess relative expression levels of select critical genes, such as CD274 (PD-L1) expression in FFPE samples shown in the figure (left part of figure). Gene expression profiles can also be used to identify the cellular origins of tumor cells (COO) and for cancer subtype stratification, such as the classification of diffuse large B-cell lymphoma (DLBCL) subtypes shown above (right part of figure).


Bidirectional coverage

Reads originating from unidirectional gene-specific primers (GSPs) result in open-ended capture of gene fusions. For clinically relevant known fusion genes, GSPs are designed to capture the fusion event from both ends, enabling independent detection of a single fusion event in a single assay, thus providing internal, orthogonal verification of these important fusions. In the adjacent example, 409 unique reads originating from ABL1 GSPs and 329 unique reads originating from BCR independently detected a BCR-ABL1 fusion. Furthermore, digital read counting of molecular barcodes (MBCs) ligated prior to amplification can be used to assess expression changes across the fusion gene to detect expression imbalance, providing a third internal confirmation of the detected fusion.

  • Provides independent verification of fusion event
  • + Expression imbalance over key events gives 3rd event verification

BCR:ABL1 fusions identified


How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2017 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.